Demenz mit Lewy-Körpern

• Literatur

• 1 McKeith IG, Galasko D, Kosaka K et al. Consensus Guidelines for the Clinical and Pathologic Diagnosis of Dementia with Lewy Bodies (DLB): report of the Consortium on DLB International Workshop. Neurology 1996; 47: 1113-1124
• 2 Luis CA, Barker WW, Gajaraj K et al. Sensitivity and specificity of three clinical criteria for dementia with Lewy bodies in an autopsy-verified sample. Int J Geriatr Psychiatry 1999; 14: 526-533
• 3 Serby M, Samuels SC. Diagnostic criteria for dementia with Lewy bodies reconsidered. Am J Geriatr Psychiatry 2001; 9: 212-216
• 4 McKeith IG, Dickson DW, Lowe J et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology 2005; 65: 1863-1872
• 5 Vann Jones SA, O’Brien JT. The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies. Psychol Med 2013; 1-11
• 6 Okazaki H, Lipkin LE, Aronson SM. Diffuse intracytoplasmic ganglionic inclusions (Lewy type) associated with progressive dementia and quadriparesis in flexion. J Neuropathol Exp Neurol 1961; 20: 237-244
• 7 Dikiy I, Eliezer D. Folding and misfolding of alpha-synuclein on membranes. Biochim Biophys Acta 2012; 1818: 1013-1018
• 8 Husnjak K, Dikic I. Ubiquitin-binding proteins: decoders of ubiquitin-mediated cellular functions. Annu Rev Biochem 2012; 81: 291-322
• 9 Goedert M, Spillantini MG, Del TK et al. 100 years of lewy pathology. Nat Rev Neurol 2013; 9: 13-24
• 10 McKeith I, Del Ser T, Spano P et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000; 356: 2031-2036
• 11 Brown DF, Dababo MA, Bigio EH et al. Neuropathologic evidence that the Lewy body variant of Alzheimer disease represents coexistence of Alzheimer disease and idiopathic Parkinson disease. J Neuropathol Exp Neurol 1998; 57: 39-46
• 12 Hamilton RL. Lewy bodies in Alzheimer’s disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol 2000; 10: 378-384
• 13 Clinton LK, Blurton-Jones M, Myczek K et al. Synergistic interactions between abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci 2010; 30: 7281-7289
• 14 Barber R, Scheltens P, Gholkar A et al. White matter lesions on magnetic resonance imaging in dementia with Lewy bodies, Alzheimer’s disease, vascular dementia, and normal aging. J Neurol Neurosurg Psychiatry 1999; 67: 66-72
• 15 Londos E, Passant U, Brun A et al. Clinical Lewy body dementia and the impact of vascular components. Int J Geriatr Psychiatry 2000; 15: 40-49
• 16 McKeith I, Mintzer J, Aarsland D et al. Dementia with Lewy bodies. Lancet Neurol 2004; 3: 19-28
• 17 Lee DR, Taylor JP, Thomas AJ. Assessment of cognitive fluctuation in dementia: a systematic review of the literature. Int J Geriatr Psychiatry 2012; 27: 989-998
• 18 Cagnin A, Gnoato F, Jelcic N et al. Clinical and cognitive correlates of visual hallucinations in dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2013; 84: 505-510
• 19 Rolma G, Jelcic N, Gnoato F et al. Combined duloxetine and benzodiazepine-induced visual hallucinations in prodromal dementia with Lewy bodies. Gen Hosp Psychiatry 2013; doi:
• 20 Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to lewy bodies in the temporal lobe. Brain 2002; 125: 391-403
• 21 Ditter SM, Mirra SS. Neuropathologic and clinical features of Parkinson’s disease in Alzheimer’s disease patients. Neurology 1987; 37: 754-760
• 22 Liu Y, Stern Y, Chun MR et al. Pathological correlates of extrapyramidal signs in Alzheimer’s disease. Ann Neurol 1997; 41: 368-374
• 23 Aarsland D, Perry R, Larsen JP et al. Neuroleptic sensitivity in Parkinson’s disease and parkinsonian dementias. J Clin Psychiatry 2005; 66: 633-637
• 24 Ferman TJ, Boeve BF, Smith GE et al. Dementia with Lewy bodies may present as dementia and rem sleep behavior disorder without parkinsonism or hallucinations. J Int Neuropsychol Soc 2002; 8: 907-914
• 25 Hibi S, Yamaguchi Y, Umeda-Kameyama Y et al. The high frequency of periodic limb movements in patients with Lewy body dementia. J Psychiatr Res 2012; 46: 1590-1594
• 26 Del Ser T, Munoz DG, Hachinski V. Temporal pattern of cognitive decline and incontinence is different in Alzheimer’s disease and diffuse Lewy body disease. Neurology 1996; 46: 682-686
• 27 Postuma RB, Gagnon JF, Pelletier A et al. Prodromal autonomic symptoms and signs in Parkinson’s disease and dementia with Lewy bodies. Mov Disord 2013; 28: 597-604
• 28 Chiba Y, Fujishiro H, Iseki E et al. Retrospective survey of prodromal symptoms in dementia with Lewy bodies: comparison with Alzheimer’s disease. Dement Geriatr Cogn Disord 2012; 33: 273-281
• 29 Stubendorff K, Aarsland D, Minthon L et al. The impact of autonomic dysfunction on survival in patients with dementia with Lewy bodies and Parkinson’s disease with dementia. PLoS ONE 2012; 7: e45451
• 30 Vardy E, Holt R, Gerhard A et al. History of a suspected delirium is more common in dementia with Lewy bodies than Alzheimer’s disease: a retrospective study. Int J Geriatr Psychiatry 2013; doi:
• 31 Creese B, Ballard C, Aarsland D et al. Determining the association of the 5httlpr polymorphism with delusions and hallucinations in Lewy body dementias. Am J Geriatr Psychiatry 2013; doi:
• 32 Thaipisuttikul P, Lobach I, Zweig Y et al. Capgras syndrome in dementia with Lewy bodies. Int Psychogeriatr 2013; 25: 843-849
• 33 Gomperts SN, Locascio JJ, Marquie M et al. Brain amyloid and cognition in Lewy body diseases. Mov Disord 2012; 27: 965-973
• 34 Litvan I, MacIntyre A, Goetz CG et al. Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol 1998; 55: 969-978
• 35 Minoshima S, Foster NL, Sima AA et al. Alzheimer’s disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol 2001; 50: 358-365
• 36 Meeus B, Theuns J, Van BC. The genetics of dementia with Lewy bodies: what are we missing?. Arch Neurol 2012; 69: 1113-1118
• 37 Salmon DP, Galasko D, Hansen LA et al. Neuropsychological deficits associated with diffuse Lewy body disease. Brain Cogn 1996; 31: 148-165
• 38 Hansen L, Salmon D, Galasko D et al. The Lewy body variant of Alzheimer’s disease: a clinical and pathologic entity. Neurology 1990; 40: 1-8
• 39 Sahgal A, Galloway PH, McKeith IG et al. Matching-to-sample deficits in patients with senile dementias of the Alzheimer and Lewy body types. Arch Neurol 1992; 49: 1043-1046
• 40 Shimomura T, Mori E, Yamashita H et al. Cognitive loss in dementia with Lewy bodies and Alzheimer disease. Arch Neurol 1998; 55: 1547-1552
• 41 Doubleday EK, Snowden JS, Varma AR et al. Qualitative performance characteristics differentiate dementia with Lewy bodies and Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2002; 72: 602-607
• 42 Yoshizawa H, Vonsattel JP, Honig LS. Early neuropsychological discriminants for Lewy body disease: an autopsy series. J Neurol Neurosurg Psychiatry 2013; doi:
• 43 Collerton D, Burn D, McKeith I et al. Systematic review and meta-analysis show that dementia with Lewy bodies is a visual-perceptual and attentional-executive dementia. Dement Geriatr Cogn Disord 2003; 16: 229-237
• 44 Noe E, Marder K, Bell KL et al. Comparison of dementia with Lewy bodies to Alzheimer’s disease and Parkinson’s disease with dementia. Mov Disord 2004; 19: 60-67
• 45 Simard M, van Reekum R, Myran D. Visuospatial impairment in dementia with Lewy bodies and Alzheimer’s disease: a process analysis approach. Int J Geriatr Psychiatry 2003; 18: 387-391
• 46 Hamilton JM, Salmon DP, Galasko D et al. A comparison of episodic memory deficits in neuropathologically-confirmed dementia with Lewy bodies and Alzheimer’s disease. J Int Neuropsychol Soc 2004; 10: 689-697
• 47 Simard M, van Reekum R, Myran D et al. Differential memory impairment in dementia with Lewy bodies and Alzheimer’s disease. Brain Cogn 2002; 49: 244-249
• 48 Simard M, van Reekum R, Cohen T. A review of the cognitive and behavioral symptoms in dementia with Lewy bodies. J Neuropsychiatry Clin Neurosci 2000; 12: 425-450
• 49 Ziebell M, Andersen BB, Pinborg LH et al. Striatal dopamine transporter binding does not correlate with clinical severity in dementia with Lewy bodies. J Nucl Med 2013; doi:
• 50 Siepel FJ, Rongve A, Buter TC et al. (123I)FP-CIT SPECT in suspected dementia with Lewy bodies: a longitudinal case study. Br Med J open 2013; 3
• 51 Colloby SJ, McParland S, O’Brien JT et al. Neuropathological correlates of dopaminergic imaging in Alzheimer’s disease and Lewy body dementias. Brain 2012; 135: 2798-2808
• 52 Nakatsuka T, Imabayashi E, Matsuda H et al. Discrimination of dementia with Lewy bodies from Alzheimer’s disease using voxel-based morphometry of white matter by statistical parametric mapping 8 plus diffeomorphic anatomic registration through exponentiated lie algebra. Neuroradiology 2013; 55: 559-566
• 53 Chow N, Aarsland D, Honarpisheh H et al. Comparing hippocampal atrophy in Alzheimer’s dementia and dementia with Lewy bodies. Dement Geriatr Cogn Disord 2012; 34: 44-50
• 54 King AE, Mintz J, Royall DR. Meta-analysis of 123I-mibg cardiac scintigraphy for the diagnosis of Lewy body-related disorders. Mov Disord 2011; 26: 1218-1224
• 55 Wennstrom M, Surova Y, Hall S et al. Low CSF levels of both alpha-synuclein and the alpha-synuclein cleaving enzyme neurosin in patients with synucleinopathy. PLoS ONE 2013; 8: e53250
• 56 Schoonenboom NS, Reesink FE, Verwey NA et al. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology 2012; 78: 47-54
• 57 Slaets S, Le BN, Martin JJ et al. Cerebrospinal fluid abeta1-40 improves differential dementia diagnosis in patients with intermediate p-tau181p levels. J Alzheimers Dis 2013; doi:
• 58 Zhang ZX, Roman GC. Worldwide occurence of Parkinson’s disease: an updated review. Neuroepidemiology 1993; 12: 195-208
• 59 Mayeux R, Stern Y, Rosenstein R. An estimate of the prevalence of dementia in idiopathic Parkinson’s disease. Arch Neurol 1988; 45: 260-262
• 60 Marder K, Flood P, Cote L et al. A pilot study of risk factors for dementia in Parkinson’s disease. Mov Disord 1990; 5: 151-161
• 61 Aarsland D, Andersen K, Larsen JP et al. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003; 60: 387-392
• 62 Riepe MW, Kassubek J, Tracik F et al. Screening for cognitive impairment in Parkinson’s disease – which marker relates to disease severity?. J Neural Transm 2006; 113: 1463-1468
• 63 Pillon B, Ertle S, Deweer B et al. Memory for spatial location in ‘de novo’ parkinsonian patients. Neuropsychologia 1997; 35: 221-228
• 64 Pillon B, Deweer B, Agid Y et al. Explicit memory in Alzheimer’s, Huntington’s, and Parkinson’s diseases. Arch Neurol 1993; 50: 374-379
• 65 Pillon B, Dubois B, Lhermitte F et al. Heterogeneity of cognitive impairment in progressive supranuclear palsy, Parkinson’s disease, and Alzheimer’s disease. Neurology 1986; 36: 1179-1185
• 66 Saint-Cyr JA, Taylor AE, Lang AE. Procedural learning and neostriatal dysfunction in man. Brain 1988; 111: 941-959
• 67 Owen AM, Doyon J, Petrides M et al. Planning and spatial working memory: a positron emission tomography study in humans. Eur J Neurosci 1996; 8: 353-364
• 68 Owen AM, James M, Leigh PN et al. Fronto-striatal cognitive deficits at different stages of Parkinson’s disease. Brain 1992; 115: 1727-1751
• 69 Holthoff VA, Vieregge P, Kessler J et al. Discordant twins with Parkinson’s disease: positron emission tomography and early signs of impaired cognitive circuits. Ann Neurol 1994; 36: 176-182
• 70 Rinne JO, Portin R, Ruottinen H et al. Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18f]fluorodopa positron emission tomographic study. Arch Neurol 2000; 57: 470-475
• 71 Boller F, Mizutani T, Roessmann U et al. Parkinson disease, dementia, and Alzheimer disease: clinicopathological correlations. Ann Neurol 1980; 7: 329-335
• 72 Laakso MP, Partanen K, Riekkinen P et al. Hippocampal volumes in Alzheimer’s disease, Parkinson’s disease with and without dementia, and in vascular dementia: an MRI study. Neurology 1996; 46: 678-681
• 73 Gotham AM, Brown RG, Marsden CD. ‘frontal’ cognitive function in patients with Parkinson’s disease ‘on’ and ‘off’ levodopa. Brain 1988; 111: 299-321
• 74 Levy G, Schupf N, Tang MX et al. Combined effect of age and severity on the risk of dementia in Parkinson’s disease. Ann Neurol 2002; 51: 722-729
• 75 Litvan I, Agid Y, Goetz C et al. Accuracy of the clinical diagnosis of corticobasal degeneration: a clinicopathologic study. Neurology 1997; 48: 119-125
• 76 Pillon B, Blin J, Vidailhet M et al. The neuropsychological pattern of corticobasal degeneration: comparison with progressive supranuclear palsy and Alzheimer’s disease. Neurology 1995; 45: 1477-1483
• 77 Schneider JA, Watts RL, Gearing M et al. Corticobasal degeneration: neuropathologic and clinical heterogeneity. Neurology 1997; 48: 959-969
• 78 Kertzman C, Robinson DL, Litvan I. Effects of physostigmine on spatial attention in patients with progressive supranuclear palsy. Arch Neurol 1990; 47: 1346-1350
• 79 Pillon B, Dubois B, Ploska A et al. Severity and specificity of cognitive impairment in Alzheimer’s, huntington’s, and Parkinson’s diseases and progressive supranuclear palsy. Neurology 1991; 41: 634-643
• 80 Robbins TW, James M, Lange KW et al. Cognitive performance in multiple system atrophy. Brain 1992; 115: 271-291
• 81 Ballard C, Aarsland D, Francis P et al. Neuropsychiatric symptoms in patients with dementias associated with cortical Lewy bodies: pathophysiology, clinical features, and pharmacological management. Drugs Aging 2013; doi:
• 82 Rolinski M, Fox C, Maidment I et al. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson’s disease dementia, and cognitive impairment in Parkinson’s disease. Cochrane Database Syst Rev 2012; (3) CD006504
• 83 Riepe MW, Wilkinson D, Forstl H et al. Additive scales in degenerative disease – calculation of effect sizes and clinical judgment. BMC Med Res Methodol 2011; 11: 169
• 84 Mori E, Ikeda M, Kosaka K. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Ann Neurol 2012; 72: 41-52